Influenza virus vaccine transdermal - Intercell USA

Drug Profile

Influenza virus vaccine transdermal - Intercell USA

Alternative Names: Influenza vaccine transdermal - Intercell USA; Needle-free influenza patch - Intercell USA

Latest Information Update: 18 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Iomai Corporation
  • Developer Intercell USA
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 29 May 2007 Clinical data added to the adverse events and Viral Infections immunogenicity sections
  • 17 Jan 2007 Iomai awarded US Department of Health and Human Services contract for the development of a dose-sparing patch for use with a pandemic influenza vaccine
  • 30 Sep 2006 Phase-I clinical trials in Influenza virus infections in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top